LLY vs VTVT: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. LLY and VTVT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined LLY and VTVT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Eli Lilly (LLY) is one of the world's largest pharmaceutical companies, currently defined by its leadership in the GLP-1 class of medicines for diabetes and obesity. Its tirzepatide molecule is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management, and these products have driven explosive revenue growth amid surging demand for metabolic treatments. Beyond GLP-1s, Lilly has a deep and diversified pipeline and franchises across diabetes, oncology, immunology, and neuroscience, including a closely watched effort in Alzheimer's disease (donanemab, marketed as Kisunla). The company invests heavily in research and in expanding manufacturing capacity to meet incretin demand. Eli Lilly was founded in 1876 and is headquartered in Indianapolis, Indiana. It has become one of the most valuable healthcare companies in the world, with the obesity and diabetes opportunity central to its growth story, balanced by a premium valuation and the eventual prospect of competition and patent expirations.

Full LLY guide

vTv Therapeutics is a clinical-stage biopharmaceutical company, meaning it has no approved products and no meaningful product revenue; its value rests on the potential of drug candidates still in testing. Its lead program is cadisegliatin (previously known as TTP399), an oral small-molecule, liver-selective glucokinase activator being developed as a potential first-in-class oral adjunctive treatment for type 1 diabetes, taken alongside insulin. The drug produced positive Phase 2 results (the Simplici-T1 study) showing improvements in blood-sugar control and time in range, and it has been granted Breakthrough Therapy designation by the FDA, a status meant to speed development of promising therapies. It is now being evaluated in a US Phase 3 trial, CATT1, with enrollment expected to complete in the second half of 2026.

Full VTVT guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• LLY drivers: GLP-1 obesity and diabetes leadership; Manufacturing scale-up.
• VTVT drivers: Cadisegliatin Phase 3 in type 1 diabetes; Cash runway and non-dilutive funding.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: LLY trades at a premium valuation, so any disappointment in obesity-drug growth, pricing, or supply can compress the multiple sharply. For VTVT, the overriding risk is binary clinical and regulatory failure: as a pre-revenue micro-cap, vTv's value depends on a small number of drug candidates, and a disappointing CATT1 result or an FDA setback could sharply cut the stock.

Pick LLY if you believe its drivers more; VTVT if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the LLY and VTVT guides.

LLY. Eli Lilly trades at a premium pharma multiple that prices in continued rapid growth from the obesity and diabetes franchise plus pipeline optionality. The valuation debate centers on how large, durable, and profitable the incretin market proves to be and how competition (chiefly Novo Nordisk and emerging oral incretins) shapes pricing and share. Figures are approximate and should be verified against the latest filings before drawing conclusions.

VTVT. Figures are approximate and tied to the asOf date; verify live numbers (current cash, burn rate, market cap, share count, and CATT1 trial timing) before acting. Standard valuation metrics like P/E do not meaningfully apply to a pre-revenue biotech; the stock is valued on the probability-weighted potential of its pipeline. Any occasional reported quarterly profit is usually driven by one-off licensing income rather than a sustainable business, so cash runway and trial milestones matter far more than reported earnings.

Headline figures (approximate, early 2026): LLY shows revenue (ttm) ~$45 to 55 billion and growing fast (verify), operating margin ~30%+ (verify), gross margin ~80% (typical for branded pharma), p/e (ttm) ~40x to 60x (premium; verify); VTVT shows stage Clinical-stage biotech; no approved products and no meaningful product revenue, market cap Micro-cap, roughly in the low hundreds of millions of dollars (varies sharply with trial news), lead program Cadisegliatin (TTP399), oral glucokinase activator, in the CATT1 Phase 3 trial for type 1 diabetes; FDA Breakthrough Therapy designation, cash position ~$98 million as of Q1 2026, aided by a $20 million Newsoara upfront; described as sufficient toward CATT1 topline data.

LLY and VTVT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined LLY and VTVT exposure against your real portfolio. It is not an investment adviser.